Christopher Bunick, MD, PhD, is a physician-scientist practicing general medical and surgical dermatology at Yale Dermatology, and is an associate professor of dermatology at the Yale School of Medicine.
Treatment for Mild to Moderate vs Moderate to Severe Atopic Dermatitis
Experts define stages of atopic dermatitis and share insight on the conventional treatment landscape for mild to moderate and moderate to severe atopic dermatitis.
Atopic Dermatitis Overview: Pathophysiology, Diagnosis, and Burden
Expert perspectives on the nature of atopic dermatitis, ranging from diagnosis and pathophysiology to the clinical and social burden it places on patients.
Plaque Psoriasis Management: Future Directions in Care
Closing out their discussion on the management of plaque psoriasis, panelists share their excitement for future directions in care.
Biologic Therapy in Plaque Psoriasis: Treating During the COVID-19 Pandemic
Experts reflect on the treatment of patients with plaque psoriasis during the COVID-19 pandemic.
Unmet Needs in Moderate to Severe Plaque Psoriasis Management
A brief discussion on the unmet needs and ongoing challenges in the treatment of plaque psoriasis.
Plaque Psoriasis Patient Case 2: Factors in Selecting 2L Therapy
Shared insight on which factors are most important in determining second-line therapy for plaque psoriasis.
Plaque Psoriasis Patient Case 2: Switching Therapy at Treatment Failure
Moving on to the second patient case, panelists discuss switching therapy at treatment failure for plaque psoriasis.
Factors in Selecting Biologic Therapy for Moderate to Severe Plaque Psoriasis
Panelists share which factors they use to determine optimal therapy in the moderate to severe plaque psoriasis setting.
Plaque Psoriasis: Biologic Therapy Toxicity Profiles
A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.
Bimekizumab’s Potential in Moderate-to-Severe Plaque Psoriasis
A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.
Moderate to Severe Plaque Psoriasis: An Overview of Biologic Agents
A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.
Moderate to Severe Plaque Psoriasis: What is the Standard of Care?
Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.
Plaque Psoriasis Case 1: Selecting a Therapeutic Class
The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.
Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy
Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.
Understanding the Psychosocial Burden of Plaque Psoriasis
Considerations for the psychological and social impact that plaque psoriasis may have on a patient.
Challenges in Diagnosing Plaque Psoriasis
Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis
Identifying Clinical Manifestations of Plaque Psoriasis
Shared insight on identifying clinical manifestations of plaque psoriasis and making a timely diagnosis.
Pathophysiology of Plaque Psoriasis and Targeted Therapies
A panel of experts review the nature of plaque psoriasis and the mechanism of action of several classes of targeted therapy.